Background: Melanoma staging has depended on depth of invasion (Breslow thickness, BT), mitotic rate (MR) and ulceration. In anticipation of the AJCC's eighth edition, variability in pathologists' assessment of these factors and consequently in tumor staging was assessed.
| INTRODUCTION
The incidence of melanoma has been increasing, nearly tripling, between 1975 and 2011, but the reasons for this apparent increase, whether natural or artefactual, have not been elucidated. 1 About 64%
of incident cases have a Breslow thickness (BT) of less than 1 mm, and are therefore defined as thin melanomas. 2 Although thin melanomas
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are generally associated with good prognoses, 15% of melanoma deaths documented in SEER (Surveillance, Epidemiology, and End
Results cancer registry) resulted from thin melanoma metastases. 2, 3 Variation in outcomes in thin melanomas has been well-studied and has greatly influenced the staging system of the American Joint Committee on Cancer (AJCC). Until recently, the 3 key staging factors, which we will term diagnostic observations, were Breslow thickness (BT), presence of ulceration and mitotic rate (MR). According to the seventh edition AJCC staging guidelines, T1 lesions have a depth of less than or equal to 1.00 mm with the distinction that category T1a
shows neither ulceration nor mitotic figures while T1b shows one or both. The remaining stages (T2-T4) are defined by BT; with the qualifiers of "a" or "b" dependent on the absence or presence of ulceration, respectively. In the eighth edition, stage T1 is defined as having a BD of <0.8 mm, and ulceration is the only stage modifier defining stages T1a and T1b.
Tumor thickness has long been established as the most important histologic predictor of patient outcomes since Breslow's landmark study. [4] [5] [6] Breslow demonstrated that lesions less than 0.76 mm in thickness rarely metastasized, and numerous studies have shown that survival is closely related to BT. Mitotic rate has also been well studied as a prognostic indicator, the second most powerful predictor of survival after BT, and was incorporated into the seventh AJCC staging criteria. 5, 7 A significant decrease in survival was found between patients with 0 and those with 1 or more mitotic figures. 3 It was recommended that sentinel lymph node (SLN) biopsies be offered to patients with T1b staging due to the 4% decreased survival at 10 years. 6 Given the AJCC's newly revised and evidence-based eighth edition, which limits T1 melanomas to a BT of 0.8 rather than 1.0 mm, and removes mitotic rate (MR) as a stage modifier, 8 it is helpful to assess the effects of removal of MR as it relates to staging using an additional national sample and methodology.
While it is known that there is substantial interobserver variability in measurement of the key diagnostic and prognostic observations, [9] [10] [11] the specific clinical importance of such variability as we move to using the AJCC eighth edition is unknown. The present study aims to assess and understand sources of discordance in melanoma staging and the potential impact on clinical care. Variability of staging observationsincluding BT, mitotic figures and ulceration-is compared among participants and in reference to a consensus panel with particular focus on observations which cross AJCC-defined staging thresholds, leading to differences in the designated stage. Additionally, since guidelines for "thin" melanoma staging in the seventh edition use cutoffs of 1.00/1.01 and 0.75/0.76 mm for BT and 1/mm 2 for MR, we consider whether rounding preferences prevail in reporting of BT, and whether these might induce participants to cross diagnostic thresholds. In the eighth edition, only a single digit after the decimal point is used.
| MATERIAL AND METHODS
A total of 240 melanocytic skin lesion patient cases were reviewed by a consensus panel of 3 experienced dermatopathologists to reach consensus on both diagnosis and treatment recommendation, as previously described. 12 In particular, agreement on mitotic rates was assessed for each case by the 3 panelists and another pathologist at a multi-headed microscope. 13 Five slide sets of melanocytic skin lesions were then identified (48 patient cases each, for a total of 240 cases).
M-Path study methods have been previously described. We then assessed whether preferences for rounding affected measures of BT and potentially diagnostic concordance. Participants are asked to report BT to the second decimal place. If a 0 or 5 appear as the second decimal in a large number of assessments, this suggests a preference for rounding: Each digit (0-9) should appear with equal probability (0.10). We determined digit preference by computing the frequencies at which each digit is selected. Because assessments are not independent of each other (assessments may be correlated within participants), we bootstrapped confidence intervals for these frequencies, redrawing at the participant level.
| RESULTS
One hundred and eighty-seven participants provided interpretations of 115 cases of invasive melanoma, resulting in a total of 2985 assessments. Characteristics of M-Path study participants have been previously described, 9 and are also depicted in the Appendix. The means and standard deviations of BT and summaries of the distributions of MR and ulceration are shown separately by seventh edition AJCC stage in Table 1 Ulceration was rarely reported by participants and experts when interpreting the reference defined T1a and T1b lesions. It was not a major factor in treatment-oriented staging in either case, as most appeared in T2+ lesions for which SLN biopsy is routinely indicated. Figure 1 .
Blue dots represent the median of the reference panel's observation, while 2 bars represent the second and third quartiles of the data (25th percentile to median and median to 75th percentile). Thus, 50% of the data are contained within the 2 bars, 25% above, and 25% below. The previous 1 mm BT cutoff is shown as a blue line, while the new 0.8 mm BT cutoff line is shown in green. It is clear from these data that while some cases show more variability across participants than others and larger average differences from the ref-
erence diagnoses than do others, the participants report BT measurements that largely follow those reported by the expert panel. In particular, it should be noted that in only 3 cases does the dot appear on the other side of the 1 mm line from the bar, suggesting that crossing this diagnostic threshold is rare when the cutoff is 1.0 mm.
When the cutoff is 0.8 mm, there is somewhat greater variation.
Specifically, in a total of 5 cases, the experts consider BT to be > 0.8, and 0.8 is within the bar (indicating that more than 25% of participants consider BT < 0.8); in 4 cases, the opposite is true, where experts consider BT is < 0.8, and more than 25% of participants consider BT to be > 0. Table 3 . The coefficients are interpreted as Table 4 .
| DISCUSSION
The seventh edition AJCC staging guidelines for invasive melanomas were based on BT, mitotic rate and ulceration. With the introduction of the newly revised eighth edition guidelines, it is important to assess how these revisions and the changes in status of individual factors (eg, mitotic rate and BT) will influence staging agreement consistency.
This is of great importance since treatment recommendations are based on the designated stage, and errors in staging could have severe Table 3 ), and therefore this may not represent the discordance rates in practice.
Participants show a clear tendency to report BT with numbers that end in a 0 or 5 in the hundreds place (P < .01), indicating a preference for rounding. This tendency is stronger, however, in thick melanomas (BT > 1.00), suggesting that participants may be paying closer attention when diagnostic thresholds affect treatment. Even though BT was not necessarily the cause of a large degree of discordance in the present study, these results suggest that care should be exercised in any redefinition of diagnostic cutoffs.
The present study shows that variation in the reporting of mitotic rate is the principal factor responsible for discordance in the staging of T1 melanoma using seventh edition AJCC system, and that this variation appears reduced with the eighth edition system. However, there is greater variation in staging around the new cutoff of 0.8 mm. , so that many of the above considerations remain applicable.
Most of the discordance between the consensus panel and participants in staging of invasive melanoma in the AJCC 7th Edition system occurs within the category of thin melanomas ( 
